Landscape Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-5,345
Closed -$578K 910
2019
Q4
$578K Buy
+5,345
New +$572K 0.04% 424
2019
Q3
Sell
-5,435
Closed -$712K 859
2019
Q2
$712K Hold
5,435
0.06% 339
2019
Q1
$735K Sell
5,435
-286
-5% -$35.6K 0.07% 326
2018
Q4
$557K Sell
5,721
-4,958
-46% -$586K 0.05% 433
2018
Q3
$1.48M Buy
10,679
+7,992
+297% +$1M 0.11% 168
2018
Q2
$334K Buy
+2,687
New +$314K 0.03% 361

Other funds holding ALXN

Landscape Capital Management's ALXN Position: Q1 2020 in Review

Landscape Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 5,345 shares — an estimated $578K sold.

Landscape Capital Management first reported a position in ALXN in Q2 2018 and held it in 6 quarters. The position peaked at $1.48M in Q3 2018. 653 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Landscape Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Landscape Capital Management sold 5,345 Alexion Pharmaceuticals shares in Q1 2020, an estimated $578K.
  • Landscape Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 6 quarters.
  • Landscape Capital Management's Alexion Pharmaceuticals position peaked at $1.48M in Q3 2018.
  • 653 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Landscape Capital Management's 13F filing for Q1 2020, filed 13 May 2020.